Date: 2012-02-10

Type of information: R&D agreement

Compound: Single Cell Network Profiling (SCNP) technology - companion diagnostics

Company: UCB (Belgium) Nodality (USA)

Therapeutic area: Immunological diseases

Type agreement:


Action mechanism:

Disease: immunology disorders


UCB and Nodality, Inc. have announced a strategic collaboration utilizing Nodality’s proprietary Single Cell Network Profiling (SCNP) technology to assist the development of several UCB compounds. The agreement establishes a multi-year collaborative investigation focusing initially on immunology disorders. Based on information generated using Nodality’s technology, the agreement also gives UCB the option to engage Nodality to develop companion diagnostics for UCB’s compounds.


Financial terms:

The terms of the agreement, whose details are not disclosed, include an upfront payment, R&D funding, and success-based milestones if all applicable development, regulatory and commercialization milestones are achieved. In addition, Nodality may be eligible for royalties on future diagnostic sales.

Latest news:

Is general: Yes